GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Other Financing

Royalty Pharma (STU:RPD) Other Financing : €689 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Other Financing?

Royalty Pharma's Other Financing for the three months ended in Dec. 2024 was €-157 Mil.

Royalty Pharma's Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 was €689 Mil.

Royalty Pharma Other Financing Historical Data

The historical data trend for Royalty Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Other Financing Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Financing
Get a 7-Day Free Trial -578.99 -532.98 -577.29 -445.36 -481.30

Royalty Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -130.72 -108.74 1,162.69 -208.53 -156.91

Royalty Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €689 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Other Financing Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Other Financing
Comparable Companies
INSM BMRN INCY SMMT MRNA EXEL ASND TECH ROIV CORT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
RPRX:USA RPRX:Mexico
Address
110 East 59th Street, New York, NY, USA, 10022
Website
https://www.royaltypharma.com
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.